Deciphering the mechanistic roles of ADARs in cancer pathogenesis, tumor immune evasion, and drug resistance
Authors:
Open Access
- 7 August 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1621585
Abstract
RNA is a fundamental biological macromolecule that undergoes several post-transcriptional modifications, including adenosine to inosine (A-to-I) editing by adenosine deaminases acting on RNA (ADARs). These essential enzymes catalyze the conversion of A-to-I in double-stranded RNA (dsRNA) molecules, influencing RNA stability, splicing, and translation, all of which impact various cellular functions. More recently, RNA editing has emerged as a pivotal mechanism in cancer biology, where ADARs, primarily ADAR1 and ADAR2, exert context-dependent roles as either oncogenic drivers or tumor suppressors. Beyond their catalytic editing function, ADARs also regulate cancer-relevant pathways through editing-independent mechanisms, including RNA binding and protein-protein interactions. Dysregulated ADAR activity facilitates carcinogenesis by altering oncogene expression, impairing tumor suppressor pathways, and reprogramming the transcriptome to promote tumor progression. Furthermore, RNA editing may contribute to tumor cell immune evasion by affecting interferon signaling and altering neoantigen presentation, as well as modulating immune surveillance. Additionally, ADAR-mediated RNA modifications contribute to therapy resistance by modifying drug targets and pathways involved in cell survival and repair. This review comprehensively analyzes the multifaceted roles of RNA-editing ADAR enzymes in cancer pathogenesis, emphasizing editing-dependent and -independent mechanisms contributing to tumor progression, immune evasion, and resistance to therapy. Moreover, we highlight the potential of ADARs as prognostic biomarkers and promising therapeutic targets in oncology. This review aims to spark novel precision oncology and cancer immunotherapy strategies by bridging molecular insights with translational applications.Keywords
This publication has 294 references indexed in Scilit:
- ADAR1 Promotes Invasion and Migration and Inhibits Ferroptosis via the FAK/AKT Pathway in Colorectal CancerMolecular Carcinogenesis, 2024
- The role of CD4+ T cells in tumor and chronic viral immune responsesMedcomm, 2023
- A‐to‐I RNA editing by ADAR and its therapeutic applications: From viral infections to cancer immunotherapyWIREs RNA, 2023
- ADAR1 is a prognostic biomarker and is correlated with immune infiltration in lung adenocarcinomaCancer Medicine, 2023
- Heterogeneous RNA editing and influence of ADAR2 on mesothelioma chemoresistance and the tumor microenvironmentMolecular Oncology, 2022
- The role of RNA editing enzyme ADAR1 in human diseaseWIREs RNA, 2021
- Epidemiology of Hepatocellular CarcinomaHepatology, 2020
- JAK–STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcomaInternational Journal of Cancer, 2019
- RNA‐editing enzymes ADAR1 and ADAR2 coordinately regulate the editing and expression of Ctn RNAFEBS Letters, 2017
- Pediatric T‐cell acute lymphoblastic leukemiaGenes, Chromosomes and Cancer, 2016